Molecular complete response to the RIN protocol (regorafenib, ipilimumab, and nivolumab) in a patient with advanced recurrent metastatic mismatch repair proficient/microsatellite stable (pMMR/MSS) rectal cancer
Therapeutic Advances in Medical Oncology · 2026-03 · 18
DOI: 10.1177/17588359261432049 ↗Kurz gefasst
Fallbericht in der Zeitschrift Therapeutic Advances in Medical Oncology, online erschienen am 19.03.2026. Verfasst von Fatima Qadri und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Oncology, Weill Cornell Medicine, New York, NY, USA. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Rectal cancer recurrence remains a major therapeutic challenge, particularly in patients unresponsive to conventional regimens. Tumors with mismatch-repair-proficient (pMMR) or microsatellite-stable (MSS) status represent the majority of colorectal cancers and are characteristically resistant to immune checkpoint inhibitors. We report a 50-year-old woman with recurrent metastatic KRAS-G12D mutant MSS rectal adenocarcinoma refractory to and with complications to standard chemotherapy regimens who achieved a complete and durable molecular response following initiation of the RIN protocol, a combination of regorafenib, ipilimumab, and nivolumab. A sustained decline in biomarker levels was observed, with both circulating tumor DNA and carcinoembryonic antigen becoming undetectable within 6 months, consistent with a complete molecular response accompanied by a marked interval decrease in FDG-avid disease and sustained radiologic and pathologic remission. This case illustrates the potential for multimodal immune modulation to overcome intrinsic resistance in pMMR/MSS in non-liver metastatic (NLM) colorectal cancer. While previous studies have demonstrated limited benefit of immunotherapy in this tumor subtype, the present findings suggest an emerging therapeutic opportunity that warrants prospective evaluation to confirm efficacy, explore the mechanistic basis, and identify biomarkers predictive of durable response beyond the absence of liver metastases. More effective combinatorial regimens like zanzalintinib and atezolizumb (STELLAR-303) trial, as well as newer generation of CTLA-4 inhibitors like botensilimab, vilastobart, and muzastotug are showing more promise for patients with MSS colorectal cancers in particular who do not have liver metastases (NLM).
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hematology and Oncology, Weill Cornell Medicine, New York, NY, USA.
- Department of Radiology, New York Presbyterian/Weill Cornell Medicine, New York, NY, USA.
- Department of Radiation Oncology, Weill Cornell Medicine, New York, NY, USA.
- Department of Surgery, Weill Cornell Medicine, New York, NY, USA.
- Oncology and Therapeutics Research, City of Hope Orange County, Irvine, California, 92618, USA.
ORCID-Profile: Fatima Qadri, Pashtoon Murtaza Kasi
Zitieren
APA
Qadri, F., Afghan, M. K., Lutfi, A., Javaid, S., Guniganti, P., Cardenes, H., Pigazzi, A., & Kasi, P. M. (2026). Molecular complete response to the RIN protocol (regorafenib, ipilimumab, and nivolumab) in a patient with advanced recurrent metastatic mismatch repair proficient/microsatellite stable (pMMR/MSS) rectal cancer. Therapeutic Advances in Medical Oncology, 18. https://doi.org/10.1177/17588359261432049
Vancouver
Qadri F, Afghan MK, Lutfi A, Javaid S, Guniganti P, Cardenes H, et al. Molecular complete response to the RIN protocol (regorafenib, ipilimumab, and nivolumab) in a patient with advanced recurrent metastatic mismatch repair proficient/microsatellite stable (pMMR/MSS) rectal cancer. Therapeutic Advances in Medical Oncology. 2026;18. doi:10.1177/17588359261432049
BibTeX
@article{Qadri2026,
author = {Qadri, Fatima and Afghan, Maaz Khan and Lutfi, Areeb and Javaid, Sana and Guniganti, Preethi and Cardenes, Higinia and Pigazzi, Alessio and Kasi, Pashtoon Murtaza},
title = {Molecular complete response to the RIN protocol (regorafenib, ipilimumab, and nivolumab) in a patient with advanced recurrent metastatic mismatch repair proficient/microsatellite stable (pMMR/MSS) rectal cancer},
journal = {Therapeutic Advances in Medical Oncology},
year = {2026},
volume = {18},
doi = {10.1177/17588359261432049}
}
EUVIMED